EDTA chelation reduced risk of death by 43% over 1-5 years in diabetics with a prior heart attack

Type 2 diabetics with a prior heart attack who were given 40 infusions of EDTA chelation therapy compared to those given a placebo had a

• 43 percent reduction in death from any cause over 1-5 years
• 41 percent overall reduction in the risk of any cardiovascular event over 1-5 years
• 40 percent reduction in the risk of death from heart disease, nonfatal stroke, or nonfatal heart attack during a 1-5 year follow-up
• 52 percent reduction in recurrent heart attacks over 1-5 years

according to a study called the Trial to Assess Chelation Therapy (TACT) that was sponsored by the National Center for Complementary and Integrative Health and the National Heart, Lung, and Blood Institute at the U.S. National Institutes of Health which was the first large-scale, multicenter clinical trial on chelation therapy in people who have had heart attacks.

EDTA chelation only benefited diabetics

EDTA chelation only benefited diabetics; it did not benefit non-diabetics.

Conclusion

Conclusion: EDTA reduces cardiovascular events in diabetics

“Post–myocardial infarction patients with diabetes mellitus aged ≥50 demonstrated a marked reduction in cardiovascular events with EDTA chelation,” the authors of the study concluded.

Subjects

Subjects: 1,708 adults aged 50 and older of whom 633 had diabetes

    “From 2003 to 2010, 1,708 adults aged 50 and older were enrolled in TACT, of whom 633 had diabetes.
    “Study participants had suffered a heart attack 6 weeks or more before enrollment (on average, the heart attack occurred about 4.5 years earlier).
    “The participants were assigned randomly to receive 40 infusions of disodium EDTA chelation solution or a placebo solution.
    “Patients also were randomly assigned to receive high doses of oral vitamins and minerals or an identical oral placebo.
    “Most participants also took standard medicines for heart attack survivors, such as aspirin, beta blockers, and statins.
    “They were followed for a minimum of 1 year and up to 5 years, with followup ending in October 2011,” as was described in a summary of the study on the NIH’s website.

Reference

Escolar E, Lamas GA, Mark DB, Boineau R, Goertz C, Rosenberg Y, Nahin RL, Ouyang P, Rozema T, Magaziner A, Nahas R, Lewis EF, Lindblad L, and Lee KL. The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT). Circ Cardiovasc Qual Outcomes, 2014 Jan; 7(1): 15-24.

Author’s Contact Info

Gervasio A. Lamas, MD
Columbia University
Division of Cardiology
Mount Sinai Medical Center
4300 Alton Rd, Suite 2070A
Miami Beach, FL 33140 USA
.(JavaScript must be enabled to view this email address)

Articles on the same subject can be found here:

• Chelation Therapy, EDTA

• Diabetes

• Heart Attack (myocardial infarction)